Depression is one of the most widely misunderstood psychological conditions in the modern world. A lot of people simply assume that it’s about people feeling said. Unfortunately, it goes a lot deeper than that since it can mean a constant, crippling absence of any sensation related to happiness or satisfaction. In an effort to curtail the damage that this condition can do, a new app equipped with an artificial intelligence is being tested right now.
One of the most effective treatments for depression is talking to psychotherapists who will work with patients through their emotional distress. However, talking about depression is not easy and plenty of people often avoid it altogether. The new app called Woebot could provide an effective bridge in such situations by giving patients an avenue for a conversation with something that’s not human, Business Insider reports.
The app was created by Stanford University clinical psychologist Alison Darcy. According to her, Woebot was based on the treatment cognitive-behavioral therapy (CBT), which is intended to measure patient reactions to challenging scenarios. Darcy also notes that while Woebot can’t replace human therapists, it can still pave the way to recovery.
“What we haven’t done a good job of in [therapy] is give people an array of options — what about the people who aren’t ready to talk to another person?” Darcy said. “This is part of the idea of meeting people where they’re at.”
As to how effective the chatbot can even be, Darcy and her team published a study that showed a marked improvement in patients suffering from depression while interacting with Woebot. Naturally, more research is needed in order to make any kind of concrete conclusion with regards to using AI-powered chatbots as official psychological treatment tools.
However, this development does signal an encouraging direction in which therapists can go. The rate of suicide among teens and young adults has seen an alarming rise over recent years. This technology could pave the way to substantially reducing that.


RFK Jr. Expands CDC Vaccine Advisory Panel's Scope Amid Legal Battles
CoreWeave Q1 2026 Revenue Surges as AI Infrastructure Demand Grows
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Judge Delays SEC Settlement With Elon Musk Over Twitter Stock Disclosure Case
Intermittent fasting doesn’t have an edge for weight loss, but might still work for some
Japan’s Top Banks to Gain Access to Anthropic’s Claude Mythos AI Model
Samsung Shares Slide as Labor Talks Intensify Ahead of Planned Strike
Nintendo Shares Tumble as Weak Forecast and Rising Switch 2 Costs Worry Investors
FDA Biologics Chief Vinay Prasad to Leave Agency in April Amid Policy Disputes
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges
CDC Monitors U.S. Travelers After Hantavirus Outbreak on Luxury Cruise Ship
GOP Lawmakers Probe Sam Altman and OpenAI Ahead of Potential IPO
Novo Nordisk Shares Tumble After CagriSema Misses Key Trial Endpoint
OpenAI-Microsoft Deal Sets $38 Billion Revenue-Sharing Cap Ahead of Potential IPO 



